Soin Neuroscience

Soin Neuroscience is a clinical-stage biotech company headquartered in Dayton, Ohio, dedicated to developing innovative non-opioid pharmacological treatments for chronic pain conditions. The company's portfolio is led by SNB-01, a novel small molecule sodium channel blocker designed to treat various forms of neuropathic pain, including diabetic peripheral neuropathy and post-herpetic neuralgia. Additionally, the company is advancing a proprietary formulation of low-dose naltrexone for the management of fibromyalgia and other chronic inflammatory pain states. Founded by Dr. Amol Soin, a leading pain management expert, the organization aims to fill the therapeutic void created by the opioid crisis with safer, non-addictive alternatives. Soin Neuroscience maintains an active research pipeline with several candidates currently in Phase 2 clinical trials. Their approach combines deep clinical expertise in pain medicine with translational science to improve patient outcomes in neurology and pain management.